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ABSTRACT
Background Globally, 2.5 million neonates died 
in 2018, accounting for 46% of under- 5 deaths. 
Multiparameter continuous physiological monitoring 
(MCPM) of neonates allows for early detection and 
treatment of life- threatening health problems. However, 
neonatal monitoring technology is largely unavailable in 
low- resource settings.
Methods In four evaluation rounds, we prospectively 
compared the accuracy of the EarlySense under- mattress 
device to the Masimo Rad- 97 pulse CO- oximeter with 
capnography reference device for heart rate (HR) and 
respiratory rate (RR) measurements in neonates in 
Kenya. EarlySense algorithm optimisations were made 
between evaluation rounds. In each evaluation round, we 
compared 200 randomly selected epochs of data using 
Bland- Altman plots and generated Clarke error grids 
with zones of 20% to aid in clinical interpretation.
Results Between 9 July 2019 and 8 January 2020, we 
collected 280 hours of MCPM data from 76 enrolled 
neonates. At the final evaluation round, the EarlySense 
MCPM device demonstrated a bias of −0.8 beats/
minute for HR and 1.6 breaths/minute for RR, and 
normalised spread between the 95% upper and lower 
limits of agreement of 6.2% for HR and 27.3% for RR. 
Agreement between the two MCPM devices met the a 
priori–defined threshold of 30%. The Clarke error grids 
showed that all observations for HR and 197/200 for RR 
were within a 20% difference.
Conclusion Our research indicates that there is 
acceptable agreement between the EarlySense and 
Masimo MCPM devices in the context of large within- 
subject variability; however, further studies establishing 
cost- effectiveness and clinical effectiveness are needed 
before large- scale implementation of the EarlySense 
MCPM device in neonates.
Trial registration number NCT03920761.
INTRODUCTION
High neonatal mortality rates persist in Sub- 
Saharan Africa, with 27 deaths/1000 live births, 
a rate 10 times higher than rates in high- resource 
settings.1 Interventions are urgently needed, partic-
ularly in low- resource African settings, if Sustain-
able Development Goal Target 3.2 of reducing 
neonatal mortality to 12 deaths/1000 live births is 
to be achieved by 2030.2
Major causes of neonatal mortality include 
complications of preterm birth, asphyxia, and infec-
tious diseases which are preventable and treatable.3 
Technologies that can detect vulnerability and 
prompt interventions have great potential to 
improve neonatal survival. Multiparameter contin-
uous physiological monitoring (MCPM) devices 
could be key in identifying high- risk neonates. 
Studies have demonstrated that monitoring of vital 
sign trends can predict clinical deterioration and 
allow for timely intervention and improvement in 
health outcomes.4–8 However, neonatal MCPM 
devices are not available in most low- resource 
settings due to barriers such as the high cost of 
equipment and a lack of health personnel with 
appropriate training.9 10
A better understanding of if and how MCPM 
devices can be adapted and optimised for use in 
neonates in low- resource settings is critical. Our 
study’s primary outcomes were agreement of heart 
What is already known on this topic?
 ► Sustainable Development Goal 3’s focus on 
treatment and prevention of acute illness 
calls for development and optimisation of 
innovations for neonatal care in low- resource 
settings.
 ► Continuous monitoring of neonatal heart and 
respiratory rates is rarely performed in low- 
resource settings due to poor availability of 
monitoring technologies and high acquisition 
costs.
 ► Almost all studies of automated monitoring 
technologies have been conducted in high- 
resource settings, making it difficult to assess 
these technologies for use in low- resource 
settings.
What this study adds?
 ► This is a novel evaluation of the accuracy 
of a contactless multiparameter continuous 
monitoring device compared with a reference 
standard in neonates in a low- resource setting.
 ► We describe a method for and some of the 
challenges in performing monitoring device 
accuracy studies in neonates.
 ► Our study indicates acceptable agreement 
between the EarlySense device and the Masimo 
Rad- 97 reference device for measurement of 
heart and respiratory rates.  on N
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rate (HR) and respiratory rate (RR) measurements comparing 
the EarlySense (EarlySense, Israel) investigational device to the 
Masimo Rad- 97 pulse CO- oximeter with capnography (Masimo 
Corporation, USA) reference device. We hypothesised that the 
EarlySense device would agree within a priori–defined thresh-
olds for HR and RR measurements when compared with the 
reference device and show minimal bias.
METHODS
Study design and procedures
We conducted an iterative prospective study at Aga Khan Univer-
sity, Nairobi (AKU- N), a tertiary healthcare facility in Kenya, to 
assess agreement of HR and RR measurements from the Early-
Sense investigational device with those from the Masimo Rad- 97 
reference device.10 The Masimo Rad- 97 device was selected 
based on its capability for high- resolution data collection and 
neonatal capnometry and pulse oximetry. EarlySense’s contact-
less wireless piezoelectric sensor can be placed under a patient’s 
mattress to detect ballistic vibrations from respiratory chest wall 
movement and cardioballistic movements from ejection of blood 
(online supplemental appendix A).
During Masimo Rad- 97 reference device verification, we 
tested functionality and estimated within- neonate and between- 
neonate variability to pre- specify thresholds for agreement 
comparisons.11 We completed an initial round of open- label data 
collection from both devices in which complete reference device 
data were shared with EarlySense prior to analysis. Three rounds 
of closed- label analysis followed, in which the first 15–30 min of 
reference device data from each neonate were provided to Early-
Sense to confirm time synchronicity across data sources (online 
supplemental appendices B, C). All reference device data were 
provided to EarlySense on completion of each subsequent round 
of data analysis to optimise HR and RR detection algorithms.
Caregivers of neonates delivered at AKU- N during the study 
period were approached for recruitment into the study and 
trained study clinicians obtained informed consent prior to 
determining eligibility for enrolment (table 1). Enrolled neonates 
were simultaneously monitored by both devices (figure 1; online 
supplemental video 1).
Data processing and selection
To ensure accurate, reliable and consistent data collection, we 
conducted the study in accordance with the Guideline for Good 
Clinical Practice/International Standards Organization (ISO) 
14 155.
We randomly selected epochs of HR and RR with suffi-
cient signal quality for each neonate recording (table 1). The 
first 5 min and last minute of recorded data, and first minute 
prior to and 5 min following any device or sensor disconnection 
were excluded to remove potentially poor- quality data typically 
present during sensor placement and removal. For the open- 
label round, we selected 20 epochs from ten different neonates. 
For each closed- label round, we selected ten epochs from 20 
different neonates. No overlapping epochs were selected, and 
missing data were excluded from analyses. Median HR and RR 
values were calculated for the selected epochs (table 1). Manual 
RR counting was performed for each epoch using capnograms 
(online supplemental appendix D). Any RR epochs meeting 
exclusion criteria were replaced with another randomly selected 
epoch (table 1). See online supplemental appendix E for more 
details.
Statistical analysis
To quantify the agreement between the EarlySense and refer-
ence devices, the normalised bias (95% CI) and the normalised 
spread between the 95% limits of agreement (LOA) were calcu-
lated by dividing the bias and spread between the 95% LOA by 
the overall reference HR or RR mean value.12 Based on a verifi-
cation phase, the acceptable a priori- defined normalised spread 
Table 1 Eligibility criteria and study definitions
Eligibility criteria
Inclusion criteria  ► Corrected age of <28 days
 ► Caregivers were willing and able to provide informed consent and were available for follow- up for the duration of the study
Exclusion criteria  ► Receiving continuous positive airway pressure or mechanical ventilation
 ► Skin abnormalities in the nasopharynx and/or oropharynx
 ► Contraindication to skin sensor application
 ► Known arrhythmia
 ► Congenital abnormality requiring major surgical intervention
 ► Any medical or psychosocial condition or circumstance that would interfere with study conduct or for which study participation could put the neonate’s 
health at risk
Study definitions
Epoch A 60 s period of time
Breath One cycle of neonate- initiated inhalation and exhalation
Breath start End of a waveform trough (low point) where the carbon dioxide level starts to ascend
Respiratory rate (RR) manual 
counting protocol
A breath was counted if the waveform peak reached either 15 mmHg or the average peak of the epoch, AND the waveform trough dipped below the average 
trough of the epoch plus 10 mmHg
 ► Each plot was counted by two independent readers and averaged
 ► If the difference in the counts was >5, a third independent reader counted the plot
 ► If the third count was within 5 breaths of either previous count, the average of the two closest counts was used
RR epoch exclusion criteria RR epoch excluded if (i) the difference between the epoch count and median RR was >10, (ii) either value was <15, (iii) the capnogram contained a digital 
artefact or (iv) if there was lack of inter- reader manual count agreement
RR median calculation For each breath in an epoch, an instantaneous RR could be calculated by the breath duration, and the median of all these instantaneous RR values in an epoch 
was then calculated
Heart rate (HR) median 
calculation
Heart beats were identified by the timing of the Masimo Rad- 97 reference device plethysmograph quality index (PO- SQI) which occur at the peak of each 
heart beat. For each heart beat in an epoch, an instantaneous HR could be calculated by the time between the previous heart beat peak and current heart 
beat peak, and the median of all these instantaneous HR values in an epoch was then calculated
Adequate signal quality EarlySense device: A signal quality score ≥0.7 for at least 50% of the epoch
Masimo Rad- 97 reference device: plethysmograph quality index (PO- SQI) threshold >150 for 100% of the epoch for HR, and capnography quality score (CO2- 
SQI) threshold ≥2 for at least 90% of the epoch for RR
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between the 95% upper and lower LOAs of 30% was selected 
for both RR and HR.11 We calculated the root- mean- square 
deviation (RMSD) for each comparison. Clarke error grids were 
constructed with zones of 20% discrepancy to improve clinical 
interpretability of results.
RESULTS
We enrolled 94 neonates from 9 July 2019 to 8 January 2020, 
76 of which were included for analysis (online supplemental 
appendix F). Three neonates withdrew prior to the minimum 
data collection time, and 15 neonates were excluded due to 
issues with data identification (incorrect date/times recorded) or 
time synchronisation (10), insufficient (less than 1 hour) length 
of recording (4) or poor data quality (1). There were six record-
ings where only one of the vital signs was usable for analysis 
due to poor data quality. There were no adverse events due to 
monitoring.
Equal numbers of female and male neonates from the neonatal 
high dependency unit (64.5%), postnatal and maternal wards 
(34.2%), and neonatal intensive care unit (1.3%) were included 
for analysis. Median gestational age was 38 (range 28–42) weeks 
and primary diagnoses were healthy post- delivery (35.5%), 
prematurity (27.6%), jaundice (17.1%), hypoglycaemic (6.6%), 
respiratory distress syndrome (5.3%), low birth weight (3.9%) 
and other (3.9%). We collected 280 hours of data (online 
supplemental appendix G), with a median recording length of 
4 hours (range 73–423 min). See online supplemental appendix 
H for additional results.
HR analysis identified a small negative average bias (range 
−1.58 to −0.55 beats/minute) with normalised spread of LOA 
meeting the a priori–defined threshold for all rounds (table 2; 
figure 2). A marked decrease in normalised spread between 95% 
LOA between closed- label rounds 2 and 3 (20.1 vs 6.2%) was 
observed. All EarlySense HR measurements were within 20% of 
the reference device values (figure 3).
RR analyses showed a small positive average bias in the Early-
Sense device (range 0.17–1.62 breaths/minute) when compared 
with reference device RR manual counts and a small negative 
average bias (range −1.65 to −0.63 breaths/minute) when 
compared with RR median values (table 2; figure 4). Normalised 
spread between 95% LOA decreased between the open- label 
and first two closed- label rounds, with results from closed- label 
rounds 2 and 3 meeting the a priori–defined threshold for both 
RR manual counts and median values. A marked decrease in 
normalised spread between 95% LOA from closed- label rounds 
1 and 2 (37.6 vs 24.8% for RR manual counts; 35.9 vs 19.2% 
for RR medians) was observed. Absolute and normalised spreads 
of 95% LOA for RR median values were consistently smaller 
than RR manual counts when comparing the EarlySense and 
reference devices. Of the data pairs from closed- label round 3, 
only three (1.5%) EarlySense RR values were outside 20% of the 
reference device values (figure 3).
Figure 1 (A) Overview of the set- up showing the Masimo Rad- 
97 device with touchscreen interface (1), pulse oximeter probe 
(2), Nomoline for capnography (3), EarlySense processing unit (4), 
EarlySense under- mattress sensor (5). (B) Close- up of the EarlySense 
sensor under a mattress. The EarlySense sensor is connected to the 
processing unit that processes, stores data and sends results wirelessly 
to the remote display unit where the data are presented.
Table 2 Results from Bland- Altman analysis for EarlySense investigational device versus Masimo Rad- 97 reference device heart rate (HR) and 
respiratory rate (RR) measurements
Open label Closed- label round 1 Closed- label round 2 Closed- label round 3
EarlySense HR compared with Masimo Rad- 97 HR
Mean Masimo Rad- 97 HR 132.3 128.2 139.1 130.2


















Normalised RMSD 5.0% 4.1% 5.1% 1.7%
EarlySense RR compared with Masimo Rad- 97 RR manual count
Mean Masimo Rad- 97 RR 48.0 51.7 54.2 48.5


















Normalised RMSD 11.9% 9.6% 6.8% 7.7%
EarlySense RR compared with Masimo Rad- 97 RR median
Mean Masimo Rad- 97 RR 50.3 53.5 56.4 50.7







(−1.9% to − 0.5%)










Normalised RMSD 10.8% 9.7% 5.1% 5.2%
LOA, limits of agreement; RMSD, root- mean- square deviation.
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We found acceptable agreement between the EarlySense and 
reference devices for measurement of HR and RR in neonates 
by the final round of analysis, as evidenced by normalised spread 
between 95% LOA values below the a priori–defined threshold 
of 30%. The EarlySense algorithms were optimised between 
closed- label rounds 1 and 2 for RR, and between closed- label 
rounds 2 and 3 for HR. Upon optimisation, a marked narrowing 
of normalised spread between 95% LOA and reduction in bias 
was observed. Clarke error grids showed that all observations 
for HR and 197/200 for RR fell in region A (20% difference) 
(figure 3).
Selection of a reference standard is key when evaluating accu-
racy of a MCPM device. While ECG is the accepted reference 
standard for HR measurement, plethysmogram- derived HR, as 
used by the Masimo Rad- 97 device, has been shown to be accu-
rate even for comparisons of HR variability that require precise 
timing in identification of the heartbeat.13 The EarlySense device 
uses ballistocardiography (BCG). In comparison with ECG, 
heartbeats are less pronounced and more difficult to detect in 
BCG signals due to a lower signal- to- noise ratio14; yet, BCG 
signals have been shown to accurately estimate HR in adults.15
We selected capnography as the RR reference method.16 
Agreement between RR measurements was impacted by within- 
neonate RR variability, which is particularly pronounced in 
neonates due to immature control of respiration, and normal and 
abnormal physiological responses such as periodic breathing and 
periods of apnoea.17 There are currently no recommended ISO 
standards for RR accuracy, though United Nations International 
Child’s Fund has suggested a maximum variability of ±2 breaths/
minute in their acute respiratory infection diagnostic aid target 
product profile.18 This threshold may be unreasonably conserva-
tive when considering a neonate breathing at 60 breaths/minute, 
where a within- neonate variation of 2 breaths/minute would 
equate to a 3.3% variation. In setting the 30% threshold for 
the spread between 95% LOA, we considered the large within- 
neonate RR variability present in the verification phase data 
and avoided setting the target agreement threshold to be more 
restrictive than the within- neonate variation.11 We chose to 
normalise the spread between 95% LOA and used a percentage 
error threshold to allow for comparison of performance over 
a wide range of RR values. Use of a ±30% error threshold for 
LOA to determine whether to accept a new method in cardiac 
output method comparison studies was proposed in 1999 and 
has since been used extensively in the field.19
We compared EarlySense RR measurements to reference device 
RR manual counts and medians. Since clinical measurement of 
RR is typically determined by counting the number of breaths 
over a 1 min period, comparison of EarlySense RR values to RR 
manual counts was used as the primary comparison. However, 
manual count methods have several limitations. Capnograms 
can contain several different breathing patterns, such as peri-
odic breathing and small- amplitude breaths, and it is unclear 
which breathing patterns should be included in a manual count 
and which should cause a minute to be excluded. In addition, 
rounding is a significant consequence of counting breaths. The 
rounding error may be as much as 6.7% if considering a RR of 
15 breaths/minute and a rounding error of 1 breath/minute. We 
Figure 2 Bland- Altman plots for heart rate (HR). (A) Open- label round. (B) Closed- label round one. (C) Closed- label round two. (D) Closed- label 
round three. Colours indicate which participant neonate is associated with the measurement pair.
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used a comparison between EarlySense RR and reference device 
RR median values since median values are more likely to reflect 
the underlying control of breathing. Medians are more robust 
than means, especially in the presence of extreme outliers, and 
are often used in automated device signal processing methods. 
This may explain the greater agreement when comparing 
the EarlySense RR to the reference device medians versus RR 
manual counts.
We reported RMSD values, as the accuracy of HR and RR has 
typically been reported as a percentage error rate (such as ±2%) 
compared with a reference standard.20 While RMSD is provided 
as a standardised metric when performing comparisons, RMSD 
does not consider the uncertainty in the reference method. In this 
evaluation, the normalised RMSD was 1.7% for HR, and 7.7% 
and 5.2% for RR manual counts and median values, respectively, 
in the final round (table 2). This was approximately 25% of the 
value of normalised spread between 95% LOA.
The study results indicate that the EarlySense MCPM device 
performs well when used to measure HR and RR as compared 
with the more invasive Masimo Rad- 97 reference device. Advan-
tages of the EarlySense device are that it is contactless and 
does not require disposable components. However, limitations 
include lack of MCPM when the neonate is not in bed, and lack 
of oxygen saturation monitoring. Notably, the Masimo Rad- 97 
capnography cannula was removed when the neonate was not 
in bed.
The accuracy of the EarlySense device was confirmed in a 
study population of high- risk adult surgical patients and in a 
small feasibility series with a paediatric and adult patient popu-
lation in a sleep laboratory and intensive care unit setting.21 22 
Other studies of monitoring technologies have been conducted 
in low- resource settings23–26; however, research conducted in 
neonates has largely been limited to studies in high- resource 
settings. Well- established methods for HR and RR monitoring 
exist, but limitations including inaccuracy, invasiveness, time- 
consuming application and high cost have prompted develop-
ment of novel technologies.27–29 Novel contactless technologies 
are attractive as they avoid discomfort and risk of skin irritation. 
However, they have limitations of their own including motion 
artefacts, poor sensor coupling, poor- quality recordings and 
dependency on adequate lighting.28 29 There is a strong need for 
additional studies evaluating neonatal monitoring technology in 
low- resource settings.
Major strengths of our study were the independence of the 
investigators conducting the analysis, robust measurement of 
RR with high- resolution capnography, manual counting of 
breaths and randomised selection of minutes for comparison. 
However, our study site was better resourced than is typical 
in the region, and it is possible that the device may not have 
performed as well in a less- resourced environment. Currently, 
we are completing our next phase at Pumwani Maternity 
Hospital in Nairobi, Kenya, the largest referral maternal 
hospital in sub- Saharan Africa and a site more representative of 
a low- resource setting.
A substantial percentage (19.1%) of neonate recordings were 
not included for analysis due to data synchronisation and data 
identification issues (incorrect dates assigned). To minimise 
uncertainty in the reference device data and to avoid the Early-
Sense device missing the a priori threshold due to poor quality 
reference device data, we removed a substantial proportion 
of reference minutes from analysis and only included minutes 
with the highest quality reference data. In addition, we did not 
study clinical correlations or outcomes and were unable to assess 
the degree to which findings represented clinically significant 
differences. In the next phase of our study, we will assess the 
clinical feasibility of the EarlySense device with regard to accu-
racy, up- time, and event detection of high and low HR and RR 
events. Many of the neonates in this study were healthy, or rela-
tively healthy, so it is possible that the agreement we observed 
may not reflect the sensor performance in critically ill neonates 
with higher or more irregular HRs and/or RRs. The EarlySense 
investigational device algorithms were developed in a cohort 
of neonates who were not critically ill to ensure that the initial 
evaluation and optimisation was performed in a more controlled 
environment, as is typically done for regulatory approval, before 
extending to more challenging cases and environments. We 
found the performance of this innovative non- invasive MCPM 
device to be promising in neonates. In a qualitative study, we 
found that healthcare administrators, healthcare providers 
Figure 3 Clarke error grids for closed- label round three 
measurements. (A) Comparison of heart rate (HR) measurements. (B) 
Comparison of EarlySense respiratory rate (RR) to Masimo Rad- 97 RR 
manual count. Each dot represents a data pair, with the colour intensity 
proportional to density of data pairs. Region A (in green) contains data 
pairs that are within 20% of the Masimo Rad- 97 device value. Region 
B (in yellow) contains data pairs not within 20% that would not lead to 
unnecessary treatment. Regions C, D and E are in red. C includes data 
pairs leading to unnecessary treatment. D includes data pairs with a 
failure in detecting low or high HR/RR events and E includes data pairs 
where low and high HR/RR events are confused.
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and caregivers considered the EarlySense device to be feasible, 
useable and acceptable.30
Moving forward, it will be valuable to evaluate the EarlySense 
device for agreement with a reference device in neonates in 
intensive or critical care. A future study assessing the agreement 
of the EarlySense device HR and RR to ECG- derived HR and 
RR would strengthen the evidence for adoption of this novel 
contactless technology. In addition, evaluating the threshold and 
adaptive alerts provided by the device, and establishing cost- 
effectiveness, and clinical effectiveness will be necessary before 
large- scale implementation can be considered.
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